BioHarvest’s VINIA Tops Resveratrol Market with $30M U.S. Sales and 85K Users
BioHarvest Sciences’ VINIA® brand achieved the No. 1 Resveratrol Polyphenol market share in under five years, generating over $30 million in U.S. revenue in 2025 and 80% of sales via its VINIA.com platform. The product boasts $85 million in revenue, more than 85,000 active users and clinical proof of enhanced arterial dilation.
1. Market Leadership Achievement
VINIA® has secured the top position in the U.S. Resveratrol Polyphenol nutraceutical category in less than five years, underscoring its rapid adoption and competitive differentiation based on its unique formulation and delivery system.
2. Sales Performance and User Base
The direct-to-consumer business generated over $30 million in U.S. revenue for full-year 2025, with approximately 80% of VINIA sales processed through VINIA.com. To date, VINIA has amassed more than 85,000 active users and $85 million in global revenue.
3. Clinical Efficacy and Botanical Synthesis Technology
VINIA’s composition, centered on piceid resveratrol and a full grape polyphenol complex, delivers up to 100-fold higher piceid levels through a protective plant-cell envelope. Clinical studies demonstrate its ability to increase arterial dilation, improving blood flow and nutrient delivery.
4. Growth Outlook and Future Applications
Leveraging VINIA as a foundational compound, the company plans to combine it with synergistic molecules to develop new nutraceutical products. Its Botanical Synthesis platform also supports contract development for external clients, positioning BioHarvest for expanded partnerships and product launches.